PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
- Conditions
- Dermatitis, AtopicEczemaSkin DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateDermatitisHypersensitivityGenetic Diseases, InbornSkin Diseases, GeneticImmune System Diseases
- Interventions
- Drug: Injectable PlaceboDrug: Oral Placebo
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 838
- Registration Number
- NCT03720470
- Locations
- 🇺🇸
Moonshine Research Center, Inc., Doral, Florida, United States
🇺🇸PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States
🇨🇦Toronto Research Centre, Toronto, Ontario, Canada
Descriptive Observational Study ALK-2016-CPHG
- Conditions
- NSCLCALK Gene Rearrangement or ROS1 Gene RearrangementCrizotinib
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT03718117
- Locations
- 🇫🇷
Centre Hospitalier General Beziers, Service De Pneumologie, Beziers, France
🇫🇷Centre Hospitalier Metropole de Savoie-Site de Chambery, Chambery, France
🇫🇷Le Mans Hospital Center, Le Mans, France
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
- Conditions
- Active Non-segmental Vitiligo
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 366
- Registration Number
- NCT03715829
- Locations
- 🇺🇸
Advanced Skin and MOHS Surgery Center, c/o TrialSpark, Inc., Chicago, Illinois, United States
🇦🇺Veracity Clinical Research Pty Ltd, Woolloongabba, Queensland, Australia
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
- Conditions
- Rhabdoid TumorSolid TumorsMedulloblastomaEwing SarcomaRhabdomyosarcomaDiffuse Intrinsic Pontine GliomaNeuroblastoma
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT03709680
- Locations
- 🇸🇰
Detska fakultna nemocnica s poliklinikou Banska Bystrica, Banska Bystrica, Slovakia
🇺🇸University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Rheumatoid Arthritis Satisfaction Outcome Research
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT03703817
- Locations
- 🇰🇷
Kyung Hee University Hospital at Gangdong / Rheumatology, Seoul, Gangdong-gu, Korea, Republic of
🇰🇷Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
🇰🇷Wonkwang University Hospital / Division of Rheumatology, Iksan, Jeonlabuk-do, Korea, Republic of
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
- Conditions
- Breast NeoplasmsColorectal NeoplasmsCarcinoma, Renal CellProstate NeoplasmsNeoplasms, Squamous CellMelanomaLiver NeoplasmsMesotheliomaPancreatic Neoplasms
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT03685591
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
- Conditions
- LeukemiaPrecursor b-Cell Lymphoblastic Leukemia-LymphomaACUTE LYMPHOBLASTIC LEUKEMIA
- Interventions
- Drug: inotuzumab ozogamicin-dose level 2Drug: Inotuzumab ozogamicin-dose level 1
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT03677596
- Locations
- 🇮🇳
Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India
🇺🇸LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
- Conditions
- Triple-negative Breast CancerNon-Small Cell Lung Cancer
- Interventions
- Biological: PF-06936308
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03674827
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT03672643
- Locations
- 🇨🇳
Eastern Theater General Hospital ,QinHuai District Medical Area, Nanjing, Jiangsu, China
🇨🇳Jilin Province Cancer Hospital, Changchun, Jilin, China
🇨🇳Sichuan Province Cancer Hospital, Chengdu, Sichuan, China
Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT03662191
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium